132089-35-1

Basic information

• Product Name: 2-(4-FLUORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER
• Synonyms: 2-(4-FLUORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER;2-(4-FLUOROPHENYL)THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER, 95+%;Ethyl 2-(4-fluorophenyl)thiazole-4-carboxylate;4-Thiazolecarboxylic acid, 2-(4-fluorophenyl)-, ethyl ester;ethyl 2-(4-fluorophenyl)-1,3-thiazole-4-carboxylate
• CAS NO: 132089-35-1
• Molecular Formula: C₁₂H₁₀FNO₂S
• Molecular Weight: 251.28
• EINECS: 201-215-5
• Product Categories: Thiazole
• Mol File: 132089-35-1.mol
• Article Data: 9

Chemical Properties

• Appearance: /
• Refractive Index: 1.563
• Storage Temp.: Sealed in dry,Room Temperature
• CAS DataBase Reference: 2-(4-FLUORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(CAS DataBase Reference)
• NIST Chemistry Reference: 2-(4-FLUORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(132089-35-1)
• EPA Substance Registry System: 2-(4-FLUORO-PHENYL)-THIAZOLE-4-CARBOXYLIC ACID ETHYL ESTER(132089-35-1)

Safety Data

• Hazardous Substances Data: 132089-35-1(Hazardous Substances Data)

Usage

Uses

2-(4-Fluorophenyl)thiazole-4-carboxylic acid ethyl ester

InChI:InChI=1/C12H10FNO2S/c1-2-16-12(15)10-7-17-11(14-10)8-3-5-9(13)6-4-8/h3-7H,2H2,1H3

Upstream product

• 1221437-17-7 C₁₂H₁₂FNO₂S 
• 70-23-5 ethyl Bromopyruvate 
• 22179-72-2 4-fluorothiobenzamide 
• 41731-52-6 2-chloro-thiazole-4-carboxylic acid ethyl ester 
• 1765-93-1 4-fluoroboronic acid 
• 1194-02-1 4-fluorobenzonitrile 
• 1332708-71-0 C₁₂H₁₂FNO₂S 

Downstream Products

• 1338373-32-2 2-(4-fluorophenyl)thiazole-4-carbohydrazide 
• 113264-13-4 4-chloromethyl-2-(4-fluoro phenyl)-thiazole 
• 863668-07-9 2-(4-fluorophenyl)-1,3-thiazole-4-carboxylic acid 
• 875858-80-3 C₁₀H₆FNOS 

Relevant articles and documents

Synthesis and biological evaluation of new 2-aryl-4-((4-aryl-1H-1,2,3-triazol-1-yl)methyl)thiazole derivatives

A series of 2-aryl-4-((4-aryl-1H-1,2,3-triazol-1-yl)methyl)thiazole derivatives (8a–p) have been synthesized. The structure of the newly synthesized compounds was determined by spectral analysis. The title compounds were screened for their preliminary ant

Discovery of 3,5-dimethylisoxazole derivatives as novel, potent inhibitors for bromodomain and extraterminal domain (BET) family

Bromodomain and extra-terminal (BET) is a promising therapeutic target for various hematologic cancers. We used the BRD4 inhibitor compound 13 as a lead compound to develop a variety of compounds, and we introduced diverse groups into the position of the compound 13 orienting toward the ZA channel. A series of compounds (14–23, 38–41, 43, 47–49) bearing triazolopyridazine motif exhibited remarkable BRD4 protein inhibitory activities. Among them, compound 39 inhibited BRD4(BD1) protein with an IC50 of 0.003 μM was superior to lead compound 13. Meanwhile, compound 39 possess activity, IC50 = 2.1 μM, in antiproliferation activity against U266 cancer cells. On the other hand, compound 39 could arrest tumor cells into the G0/G1 phase and induce apoptosis, which was consistent with its results in inhibiting cell proliferation. Biological and biochemical data suggest that BRD4 protein might be a therapeutic target and that compound 39 is an excellent lead compound for further development.

Synthesis, antitubercular and antimicrobial potential of some new thiazole substituted thiosemicarbazide derivatives

The increase in antibiotic resistance due to multiple factors has warranted the need for search of new compounds which are active against multidrug resistant pathogens. In this context a small focused library of thiosemicarbazide derivatives of 2-arylthiazole-4-carbaldehyde, 4-methyl-2-arylthiazole-5-carbaldehyde and 1-(4-methyl-2-arylthiazol-5-yl) ethanone, (5a–l) has been synthesized. The title compounds were screened for inhibitory activity against Mycobacterium tuberculosis H37Ra (ATCC 25177) and Mycobacterium bovis Bacille Calmette Guerin (ATCC 35743) strains. The synthesized compounds, 5a–l were further assayed for their cytotoxic activity against the two human cancer cell lines, HeLa and human colon carcinoma 116 cell lines and showed no significant cytotoxic activity against these two cell lines at the maximum concentration evaluated. Further, the synthesized compounds were found to have potential antibacterial activity against Gram-negative bacteria, Escherichia coli, Pseudomonas flurescence and Gram-positive bacteria, Staphylococcus aureus, Bacillus subtilis. Most of the synthesized compounds showed moderate activity against fungal strain Candida albicans. This study provides valuable directions to our ongoing endeavor of rationally designing more potent antimycobacterial agent.